| Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial C Steenholdt, J Brynskov, OØ Thomsen, LK Munck, J Fallingborg, ... Gut 63 (6), 919-927, 2014 | 561 | 2014 |
| Tumor necrosis factor inhibitors for inflammatory bowel disease OH Nielsen, MA Ainsworth New England Journal of Medicine 369 (8), 754-762, 2013 | 405 | 2013 |
| Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease C Steenholdt, K Bendtzen, J Brynskov, OØ Thomsen, MA Ainsworth Scandinavian journal of gastroenterology 46 (3), 310-318, 2011 | 227 | 2011 |
| Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn … MA Ainsworth, K Bendtzen, J Brynskov Official journal of the American College of Gastroenterology| ACG 103 (4 …, 2008 | 191 | 2008 |
| Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies K Bendtzen, M Ainsworth, C Steenholdt, OØ Thomsen, J Brynskov Scandinavian journal of gastroenterology 44 (7), 774-781, 2009 | 179 | 2009 |
| Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease C Steenholdt, M Svenson, K Bendtzen, OØ Thomsen, J Brynskov, ... Alimentary pharmacology & therapeutics 34 (1), 51-58, 2011 | 178 | 2011 |
| Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-α in ulcerative colitis OH Nielsen, P Gionchetti, M Ainsworth, B Vainer, M Campieri, ... The American journal of gastroenterology 94 (10), 2923-2928, 1999 | 170 | 1999 |
| Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post HocAnalysis of a … C Steenholdt, K Bendtzen, J Brynskov, OØ Thomsen, MA Ainsworth Official journal of the American College of Gastroenterology| ACG 109 (7 …, 2014 | 162 | 2014 |
| CFTR mediates cAMP-and Ca2+-activated duodenal epithelial HCO3-secretion DL Hogan, DL Crombie, JI Isenberg, P Svendsen, ... American Journal of Physiology-Gastrointestinal and Liver Physiology 272 (4 …, 1997 | 148 | 1997 |
| Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD MT Frederiksen, MA Ainsworth, J Brynskov, OØ Thomsen, K Bendtzen, ... Inflammatory bowel diseases 20 (10), 1714-1721, 2014 | 133 | 2014 |
| Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease C Steenholdt, MA Ainsworth, M Tovey, TW Klausen, OØ Thomsen, ... Therapeutic drug monitoring 35 (4), 530-538, 2013 | 131 | 2013 |
| Gastroduodenal bicarbonate secretion DL Hogan, MA Ainsworth, JI Isenberg Alimentary pharmacology & therapeutics 8 (5), 475-488, 1994 | 126 | 1994 |
| Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists C Lallemand, N Kavrochorianou, C Steenholdt, K Bendtzen, ... Journal of immunological methods 373 (1-2), 229-239, 2011 | 122 | 2011 |
| Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease C Steenholdt, M Al-Khalaf, J Brynskov, K Bendtzen, O Thomsen, ... Inflammatory bowel diseases 18 (12), 2209-2217, 2012 | 120 | 2012 |
| Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies C Steenholdt, K Bendtzen, J Brynskov, MA Ainsworth Inflammatory bowel diseases 22 (8), 1999-2015, 2016 | 118 | 2016 |
| Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study C Steenholdt, A Molazahi, MA Ainsworth, J Brynskov, OØ Thomsen, ... Scandinavian journal of gastroenterology 47 (5), 518-527, 2012 | 114 | 2012 |
| Management of iron-deficiency anemia in inflammatory bowel disease: a systematic review OH Nielsen, M Ainsworth, M Coskun, G Weiss Medicine 94 (23), e963, 2015 | 110 | 2015 |
| Acid-stimulated duodenal bicarbonate secretion involves a CFTR-mediated transport pathway in mice DL Hogan, DL Crombie, JI Isenberg, P Svendsen, OBS De Muckadell, ... Gastroenterology 113 (2), 533-541, 1997 | 109 | 1997 |
| Individualized therapy is a long-term cost-effective method compared to dose intensification in Crohn’s disease patients failing infliximab C Steenholdt, J Brynskov, OØ Thomsen, LK Munck, J Fallingborg, ... Digestive diseases and sciences 60, 2762-2770, 2015 | 93 | 2015 |
| Intestinal Permeability of 51Cr-labelled Ethylenediaminetetraacetic Acid in Patients with Crohn's Disease and Their Healthy Relatives M Ainsworth, J Eriksen, JWÅV Rasmussen, OB Schaffalitzky Scandinavian journal of gastroenterology 24 (8), 993-998, 1989 | 88 | 1989 |
Ole Haagen NielsenProfessor of Medicine, Dept. of Gastroenterology, Herlev Hospital, University of Copenhagen, DenmarkΗ διεύθυνση ηλεκτρονικού ταχυδρομείου έχει επαληθευτεί στον τομέα dadlnet.dk
